ANDERSON VICENTE DE PAULA
Índice h a partir de 2011
7
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- The Torque Teno Virus Titer in Saliva Reflects the Level of Circulating CD4(+) T Lymphocytes and HIV in Individuals Undergoing Antiretroviral Maintenance Therapy(2022) HONORATO, Layla; WITKIN, Steven S.; MENDES-CORREA, Maria Cassia; TOSCANO, Ana Luiza Castro Conde; LINHARES, Iara Moreno; PAULA, Anderson Vicente de; PAIAO, Heuder Gustavo Oliveira; PAULA, Vanessa Salete de; LOPES, Amanda de Oliveira; LIMA, Silvia Helena; RAYMUNDI, Vanessa de Cassia; FERREIRA, Noely Evangelista; SILVA JUNIOR, Almir Ribeiro da; ABRAHIM, Karim Yaqub; BRAZ-SILVA, Paulo Henrique; TOZETTO-MENDOZA, Tania ReginaIntroductionTorque teno virus (TTV) is a non-pathogenic virus present in body fluids. Its titer in the circulation increases in association with immune suppression, such as in HIV-infected individuals. We evaluated if the TTV titer in saliva from HIV-positive individuals undergoing antiretroviral therapy (ART) was related to the circulating CD4+ T lymphocyte concentration and the HIV titer. MethodsSaliva was collected from 276 asymptomatic individuals undergoing ART, and an additional 48 individuals positive for AIDS-associated Kaposi's Sarcoma (AIDS-KS). The salivary TTV titer was measured by gene amplification analysis. The circulating CD4+ T lymphocyte and HIV levels were obtained by chart review. ResultsTTV was detectable in saliva from 80% of the asymptomatic subjects and 87% of those with AIDS-KS. In the asymptomatic group the median log(10) TTV titer/ml was 3.3 in 200 males vs. 2.4 in 76 females (p < 0.0001). TTV titer/ml was 3.7 when HIV was acquired by intravenous drug usage, 3.2 when by sexual acquisition and 2.4 when blood transfusion acquired. The salivary TTV titer was inversely correlated with the circulating CD4+ T lymphocyte level (p < 0.0001) and positively correlated with the circulating HIV concentration (p = 0.0005). The median salivary TTV titer and circulating HIV titer were higher, and the CD4+ count was lower, in individuals positive for AIDS-KS than in the asymptomatic subjects (p < 0.0001). ConclusionThe TTV titer in saliva is a potential biomarker for monitoring immune status in individuals undergoing ART.
- An international, interlaboratory ring trial confirms the feasibility of an extraction-less ""direct"" RT-qPCR method for reliable detection of SARS-CoV-2 RNA in clinical samples(2022) MILLS, Margaret G.; BRUCE, Emily; HUANG, Meei-Li; CROTHERS, Jessica W.; HYRIEN, Ollivier; OURA, Christopher A. L.; BLAKE, Lemar; JORDAN, Arianne Brown; HESTER, Susan; WEHMAS, Leah; MARI, Bernard; BARBY, Pascal; LACOUX, Caroline; FASSY, Julien; VIAL, Pablo; VIAL, Cecilia; MARTINEZ, Jose R. W.; OLADIPO, Olusola Olalekan; INUWA, Bitrus; SHITTU, Ismaila; MESEKO, Clement A.; CHAMMAS, Roger; SANTOS, Carlos Ferreira; DIONISIO, Thiago Jose; GARBIERI, Thais Francini; PARISI, Viviane Aparecida; MENDES-CORREA, Maria Cassia; PAULA, Anderson V. de; ROMANO, Camila M.; GOES, Luiz Gustavo Bentim; MINOPRIO, Paola; CAMPOS, Angelica C.; CUNHA, Marielton P.; VILELA, Ana Paula P.; NYIRENDA, Tonney; MKAKOSYA, Rajhab Sawasawa; MUULA, Adamson S.; DUMM, Rebekah E.; HARRIS, Rebecca M.; MITCHELL, Constance A.; PETTIT, Syril; BOTTEN, Jason; JEROME, Keith R.Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is used worldwide to test and trace the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ""Extraction-less"" or ""direct"" real time-reverse transcription polymerase chain reaction (RT-PCR) is a transparent and accessible qualitative method for SARS-CoV-2 detection from nasopharyngeal or oral pharyngeal samples with the potential to generate actionable data more quickly, at a lower cost, and with fewer experimental resources than full RT-qPCR. This study engaged 10 global testing sites, including laboratories currently experiencing testing limitations due to reagent or equipment shortages, in an international interlaboratory ring trial. Participating laboratories were provided a common protocol, common reagents, aliquots of identical pooled clinical samples, and purified nucleic acids and used their existing in-house equipment. We observed 100% concordance across laboratories in the correct identification of all positive and negative samples, with highly similar cycle threshold values. The test also performed well when applied to locally collected patient nasopharyngeal samples, provided the viral transport media did not contain charcoal or guanidine, both of which appeared to potently inhibit the RT-PCR reaction. Our results suggest that direct RT-PCR assay methods can be clearly translated across sites utilizing readily available equipment and expertise and are thus a feasible option for more efficient COVID-19 coronavirus disease testing as demanded by the continuing pandemic.
- Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Shedding and Predictors of Viral Culture Positivity on Vaccinated Healthcare Workers With Mild Coronavirus Disease 2019(2022) LUNA-MUSCHI, Alessandra; NOGUERA, Saidy Vasconez; BORGES, Igor C.; V, Anderson De Paula; CORTES, Marina Farrel; LAROCCA, Carolina; MARI, Julia Ferreira; GUIMARAES, Lara Silva Pereira; TORRES, Pablo Munoz; SCACCIA, Nazareno; VILLAS-BOAS, Lucy S.; JR, Almir Ribeiro da Silva; ANDRADE, Pamela S.; TEIXEIRA, Juliana C.; ESCADAFAL, Camille; OLIVEIRA, Vitor Falcao de; TOZETTO-MENDOZA, Tania R.; MENDES-CORREA, Maria Cassia; LEVIN, Anna S.; SABINO, Ester C.; COSTA, Silvia F.We evaluated the duration of viral culture positivity compared to rapid antigen test (RAT) and real-time reverse-transcription polymerase chain reaction (RT-PCR) in mild Omicron infection. Vaccinated persons are potentially transmissible up to day 7. RAT and RT-PCR are predictors of viral culture positivity. In this prospective cohort of 30 vaccinated healthcare workers with mild Omicron variant infection, we evaluated viral culture, rapid antigen test (RAT), and real-time reverse-transcription polymerase chain reaction (RT-PCR) of respiratory samples at days 5, 7, 10, and 14. Viral culture was positive in 46% (11/24) and 20% (6/30) of samples at days 5 and 7, respectively. RAT and RT-PCR (Ct <= 35) showed 100% negative predictive value (NPV), with positive predictive values (PPVs) of 32% and 17%, respectively, for predicting viral culture positivity. A lower RT-PCR threshold (Ct <= 24) improved culture prediction (PPV = 39%; NPV = 100%). Vaccinated persons with mild Omicron infection are potentially transmissible up to day 7. RAT and RT-PCR might be useful tools for shortening the isolation period.
- Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster(2022) SILVA JR., Almir Ribeiro da; VILLAS-BOAS, Lucy Santos; PAULA, Anderson Vicente de; TOZETTO-MENDOZA, Tania Regina; HONORATO, Layla; WITKIN, Steven S.; MENDES-CORREA, Maria Cassia
- Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination(2022) SILVA JR., Almir Ribeiro da; VILLAS-BOAS, Lucy Santos; TOZETTO-MENDOZA, Tania Regina; HONORATO, Layla; PAULA, Anderson de; WITKIN, Steven S.; MENDES-CORREA, Maria CassiaVaccination is a fundamental tool to prevent SARS-CoV-2 infection and to limit the COVID-19 pandemic. The emergence of SARS-CoV-2 variants with multiple mutations has raised serious concerns about the ability of neutralizing antibody responses elicited by prior vaccination to effectively combat these variants. The neutralizing capacity against the Gamma, Delta and Omicron variants of sera from individuals immunized with the CoronaVac vaccine remains incompletely determined. The present study evaluated 41 health care workers at the Faculdade de Medicina of the Universidade de Sao Paulo, in Sao Paulo, Brazil, naive to previous SARS-CoV-2 infection, who were vaccinated with two doses of the CoronaVac SARS-CoV-2 vaccine 28 days apart. Neutralizing antibody levels against the Gamma, Delta, and Omicron variants were measured at 32 and 186 days after the second vaccination. We also measured neutralizing antibodies against Omicron in 34 of these individuals following a subsequent booster immunization with the Pfizer vaccine. Quantification of neutralizing antibodies was performed using the Cytopathic Effect-based Virus Neutralization test. Neutralization antibody activity against the Gamma, Delta and Omicron variants was observed in 78.0%, 65.9% and 58.5% of serum samples, respectively, obtained at a mean of 32 days after the second immunization. This decreased to 17.1%, 24.4% and 2.4% of sera having activity against Delta, Gamma and Omicron, respectively, at 186 days post-vaccination. The median neutralizing antibody titers at 32 days were 1:40, 1:20 and 1:20 against Gamma, Delta and Omicron, respectively, and decreased to an undetectable median level against all variants at the later time. A booster immunization with the Pfizer vaccine elicited neutralizing antibodies against Omicron in 85% of subjects tested 60 days after vaccination. We conclude that two doses of the CoronaVac vaccine results in limited protection of short duration against the Gamma, Delta and Omicron SARS-CoV-2 variants. A booster dose with the Pfizer vaccine induced antibody neutralizing activity against Omicron in most patients which was measurable 60 days after the booster.
- Saliva as a reliable sample for COVID-19 diagnosis in paediatric patients(2022) FELIX, Alvina C.; V, Anderson de Paula; RIBEIRO, Andreia C.; SILVA, Francini C. da; INEMAMI, Marta; COSTA, Angela A.; LEAL, Cibele O. D.; FIGUEIREDO, Walter M.; SARMENTO, Dmitry J. S.; SASSAKI, Tatiana A.; PANNUTI, Claudio S.; BRAZ-SILVA, Paulo H.; ROMANO, Camila Malta
- Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant(2022) VILLAS-BOAS, Lucy Santos; PAULA, Anderson Vicente de; SILVA, Almir Ribeiro da; PAIAO, Heuder Gustavo Oliveira; TOZETTO-MENDOZA, Tania Regina; MANULI, Erika Regina; LEAL, Fabio Eudes; FERRAZ, Andrea de Barros Coscelli; SABINO, Ester Cerdeira; BIERRENBACH, Ana Luiza; WITKIN, Steven Sol; MENDES-CORREA, Maria CassiaObjectives: The aim of the present study was to evaluate if neutralizing antibody responses induced by infection with the SARS-CoV-2 strain that was dominant at the beginning of the pandemic or by the Gamma variant was effective against the Omicron variant. Methods: Convalescent sera from 109 individuals, never exposed to a SARS-CoV-2 vaccine, who had mild or moderate symptoms not requiring hospitalization following either a documented SARS-CoV-2 ancestral strain infection or a Gamma variant infection, were assayed for in vitro neutralizing antibody activity against their original strains and the Omicron variant. Results: Following an infection with the ancestral strain, 56 (93.3%), 45 (77.6%) and 1 (1.7%) serum sample were positive for neutralizing antibodies against the ancestral, Gamma variant, and Omicron variant, respectively. After infection with the Gamma variant, 43 (87.8%) and 2 (4.1%) sera were positive for neutralizing antibodies against the Gamma and Omicron variants, respectively. Conclusions: Neutralizing antibodies generated following mild or moderate infection with the SARS-CoV-2 ancestral strain or the Gamma variant are not protective against the Omicron variant.